0
0
In a significant scientific breakthrough, a team of researchers from the Indian Institute of Technology (IIT) (BHU), Uttar Pradesh, has developed a miniaturized diagnostic device capable of detecting early-stage bone cancer with remarkable precision. The innovation, led by Dr. Pranjal Chandra from the School of Biochemical Engineering, is designed to identify osteopontin (OPN), a crucial biomarker associated with osteosarcoma—a highly aggressive form of bone cancer that predominantly affects children and adolescents.
Key Features of the Device
-
The device is reagent-free, portable, and cost-effective, making it particularly suitable for use in rural and resource-limited healthcare settings.
-
It operates similarly to a glucose meter, utilizing a custom sensor surface composed of gold and redox-active nanomaterials to enable quick, accurate, and on-the-spot detection of OPN.
-
Unlike current diagnostic methods for OPN, which are often expensive and time-consuming, this new device offers rapid results with minimal equipment.
Potential Impact
The device is designed as a reagent-less immunosensor, enabling affordable and immediate testing. This is especially significant for rural areas, where early cancer detection is frequently delayed due to a lack of accessible diagnostic tools. Given the rising incidence and mortality rates of cancer in India, the development of such technology addresses a critical public health need1.
Director Prof. Amit Patra praised the innovation, calling it “a prime example of technology with a human face,” and highlighted its alignment with national initiatives like Make in India and Start-up India. The research findings have been published in the prestigious journal Nanoscale (Royal Society of Chemistry, UK).
Next Steps
A patent application has been filed for the device, and efforts are underway to adapt the prototype into a smartphone-compatible diagnostic kit, further expanding its potential for remote healthcare access.
“This technology simplifies cancer detection and empowers primary health centres,” said Prof. Chandra.
Disclaimer:
This article is based on information available as of June 27, 2025, and reflects the findings and statements of the researchers involved. The device is currently in the prototype stage, and while promising, it is not yet commercially available or approved for widespread clinical use. Further validation, regulatory approvals, and real-world testing are required before it can be adopted in routine medical practice.
